Psyence Biomedical Ltd. Common Shares

PBM · NASDAQ · Healthcare / Biotechnology

3.15USD+0.06 (+1.78%)

Price History

Full chart

Market Stats

Previous Close3.09

Open3.14

Day Range3.08 – 3.56

52-Week Range1.92 – 28.13

Volume43.25K

Market Cap21.61M

P/E (TTM)0.00

Forward P/E0.00

EPS-11.70

Dividend Yield0.00%

Beta1.73

50-Day Avg4.30

200-Day Avg8.49

About

Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.

Company Details

SectorHealthcare
IndustryBiotechnology
CEOMr. Jody Aufrichtig
Employees12
Headquarters121 Richmond Street West, Toronto, ON, Canada, M5H 2K1, USA
Websitehttps://psyencebiomed.com

Leadership

Mr. Jody AufrichtigCo-Founder, Executive Chairman & CEO · b. 1974
Mr. Warwick Ron Corden-LloydCFO & Director · b. 1980
Dr. Neil Maresky M.D.Global Head of Clinical Development · b. 1964
Ms. Taryn VosGeneral Counsel

Financials

Income Statement

Currency: USD	2022-03-31	2023-03-31	2024-03-31	2025-03-31	2026-03-31
Total Revenue	0	0	0	0	0
Cost of Revenue	-	-	240	4.27K	-
Gross Profit	-	-	-240	-4.27K	-
Operating Expense	-	-	2.75M	3.66M	-
Operating Income	-334.29K	-4.38M	-2.75M	-3.66M	-6.24M
EBITDA	10.49M	10.77M	-51.11M	1.03M	-6.92M
Net Income	8.23M	8.01M	-51.16M	1.01M	-6.94M
R&D	137.24K	1.61M	954.59K	342.17K	1.47M
Interest Expense	-	0	52.94K	9.27K	9.52K

Balance Sheet

Currency: USD	2021-03-31	2022-03-31	2023-03-31	2024-03-31	2025-03-31	2026-03-31
Total Assets	4.90M	326.55M	258.93M	1.13M	7.32M	17.57M
Total Liabilities	101.08K	16.38M	14.27M	12.10M	594.37K	623.19K
Total Equity	4.80M	236.65M	244.66M	-10.97M	6.72M	16.94M
Cash	4.75M	431.90K	15.96K	762.80K	6.14M	7.44M
Total Debt	-	-	685.00K	10.45M	-	-
Net Debt	-4.75M	-431.90K	669.04K	9.69M	-6.14M	-7.44M

Cash Flow

Currency: USD	2022-03-31	2023-03-31	2024-03-31	2025-03-31	2026-03-31
Operating Cash Flow	-1.07M	-2.15K	-2.95M	-3.73M	-8.14M
Investing Cash Flow	-32.04K	-	-5.73K	-16.23K	-4.51M
Financing Cash Flow	-1.63M	1.59K	2.35M	9.15M	13.96M
Capital Expenditure	0	0	5.73K	9.88K	500.23K
Free Cash Flow	-839.17K	-519.60K	-2.95M	-3.74M	-8.64M
FCF to OCF	78.46%	24133.91%	100.19%	100.26%	106.14%

Earnings

Report Date	Oct 21, 2021	Dec 31, 2021	Apr 1, 2022	Aug 15, 2022	Nov 14, 2022	Mar 23, 2023	Mar 31, 2023	Jun 30, 2023	Sep 30, 2023	Sep 30, 2024	Jan 23, 2025	Jun 25, 2025	Nov 20, 2025	Sep 28, 2026
EPS Estimate	0.00	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00	-
EPS Actual	0.25	1.59	0.25	0.07	0.03	0.05	-0.01	-0.05	-0.53	0.04	4.06	-99.97	-0.51	-
Surprise	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Timing	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Key Statistics & Ratios

Market Cap21.61M

Enterprise Value24.60M

Trailing P/E0.00

Forward P/E0.00

Price / Sales0.00

Price / Book1.42

EPS-11.70

Book Value7.39

Revenue (TTM)0

Gross Profit (TTM)0

EBITDA-6.23M

Profit Margin0.00%

Operating Margin0.00%

Return on Equity-58.62%

Return on Assets-31.33%

Shares Outstanding3.81M

Shares Float2.61M

Beta1.73

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Ownership Breakdown

Institutions: 9.72%
Insiders: 2.97%
Retail / Other: 87.31%

Top Institutional Holders

Parallel Advisors, LLC
151.25K3.97%
AdvisorShares Investments, LLC
122.18K3.20%
Citadel Advisors Llc
11.69K0.31%
Stonehage Fleming Financial Services Holdings Ltd
890.00%
Bank of America Corp
00.00%

Top Fund Holders

AdvisorShares Psychedelics ETF
175.69K4.61%

Stock Splits

Feb 2, 20264:25
May 5, 2025100:797
Nov 26, 20241:75